Craft

BioXcel Therapeutics

Stock Price

$0.7

2024-10-29

Market Capitalization

$29 M

2024-10-29

Revenue

$642 K

FY, 2025

BioXcel Therapeutics Summary

Company Summary

Overview
BioXcel Therapeutics is a biopharmaceutical company that focuses on artificial intelligence for neuroscience. It offers an orally dissolving sublingual film formulation of dexmedetomidine in the treatment of psychiatric and neurological disorders, as well as a sublingual film for the acute treatment of schizophrenia or bipolar disorders, etc. The company also provides an AI platform for drug development.
Type
Public
Status
Active
Founded
2017
HQ
New Haven, CT, US | view all locations
Website
https://www.bioxceltherapeutics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Vimal Mehta

    Vimal Mehta, CEO, Founder, Director

  • Peter Mueller

    Peter Mueller, Chairman of the Board

  • Frank D. Yocca

    Frank D. Yocca, Chief Scientific Officer

  • June Bray

    June Bray, Director

    LocationsView all

    1 location detected

    • New Haven, CT HQ

      United States

      555 Long Wharf Dr 12th floor

    BioXcel Therapeutics Financials

    Summary Financials

    Revenue (FY, 2025)
    $642.0K
    Gross profit (FY, 2025)
    $478.0K
    Net income (FY, 2025)
    ($69.9M)
    Cash (FY, 2025)
    $28.4M
    EBIT (FY, 2025)
    ($50.5M)
    Enterprise value
    $135.2M

    Footer menu